Lingohr Asset Management GmbH Acquires 40,821 Shares of BioNTech SE Sponsored ADR $BNTX

Lingohr Asset Management GmbH boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 598.4% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 47,643 shares of the company’s stock after purchasing an additional 40,821 shares during the quarter. Lingohr Asset Management GmbH’s holdings in BioNTech were worth $4,699,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also made changes to their positions in the company. Royal Bank of Canada increased its holdings in shares of BioNTech by 95.9% in the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares during the period. NewEdge Advisors LLC acquired a new position in BioNTech during the 1st quarter valued at about $167,000. Mirae Asset Global Investments Co. Ltd. raised its stake in BioNTech by 14.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,109 shares of the company’s stock valued at $437,000 after buying an additional 533 shares during the last quarter. Shell Asset Management Co. raised its position in shares of BioNTech by 15.3% in the 2nd quarter. Shell Asset Management Co. now owns 40,610 shares of the company’s stock valued at $4,324,000 after purchasing an additional 5,398 shares during the last quarter. Finally, Aberdeen Group plc boosted its stake in BioNTech by 87.2% in the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after purchasing an additional 336,260 shares in the last quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BNTX shares. Berenberg Bank reiterated a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and upped their price objective for the company from $115.00 to $142.00 in a report on Friday, January 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. TD Cowen restated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Finally, JPMorgan Chase & Co. dropped their target price on BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a report on Thursday, October 23rd. Eleven analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $140.03.

BioNTech Trading Down 2.6%

NASDAQ BNTX opened at $113.75 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The stock has a market capitalization of $25.61 billion, a P/E ratio of -43.25 and a beta of 1.40. The firm’s 50-day moving average is $101.09 and its two-hundred day moving average is $103.89. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $124.98.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of $0.75 by ($0.89). The firm had revenue of $1.78 billion during the quarter, compared to analyst estimates of $1.21 billion. BioNTech had a negative net margin of 17.91% and a negative return on equity of 3.03%. The business’s revenue was up 22.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.81 earnings per share. On average, sell-side analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.